Literature DB >> 1296607

Percutaneous absorption of drugs.

R C Wester1, H I Maibach.   

Abstract

The skin is an evolutionary masterpiece of living tissue which is the final control unit for determining the local and systemic availability of any drug which must pass into and through it. In vivo in humans, many factors will affect the absorption of drugs. These include individual biological variation and may be influenced by race. The skin site of the body will also influence percutaneous absorption. Generally, those body parts exposed to the open environment (and to cosmetics, drugs and hazardous toxic substances) are most affected. Treating patients may involve single daily drug treatment or multiple daily administration. Finally, the body will be washed (normal daily process or when there is concern about skin decontamination) and this will influence percutaneous absorption. The vehicle of a drug will affect release of drug to skin. On skin, the interrelationships of this form of administration involve drug concentration, surface area exposed, frequency and time of exposure. These interrelationships determine percutaneous absorption. Accounting for all the drug administered is desirable in controlled studies. The bioavailability of the drug then is assessed in relationship to its efficacy and toxicity in drug development. There are methods, both quantitative and qualitative, in vitro and in vivo, for studying percutaneous absorption of drugs. Animal models are substituted for humans to determine percutaneous absorption. Each of these methods thus becomes a factor in determining percutaneous absorption because they predict absorption in humans. The relevance of these predictions to humans in vivo is of intense research interest. The most relevant determination of percutaneous absorption of a drug in humans is when the drug in its approved formulation is applied in vivo to humans in the intended clinical situation. Deviation from this scenario involves the introduction of variables which may alter percutaneous absorption.

Entities:  

Mesh:

Year:  1992        PMID: 1296607     DOI: 10.2165/00003088-199223040-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  29 in total

1.  Studies on the chemical composition of human epidermal lipids.

Authors:  R P REINERTSON; V R WHEATLEY
Journal:  J Invest Dermatol       Date:  1959-01       Impact factor: 8.551

2.  Controlled release of benzoyl peroxide from a porous microsphere polymeric system can reduce topical irritancy.

Authors:  R C Wester; R Patel; S Nacht; J Leyden; J Melendres; H Maibach
Journal:  J Am Acad Dermatol       Date:  1991-05       Impact factor: 11.527

3.  Are there age and racial differences to methyl nicotinate-induced vasodilatation in human skin?

Authors:  R H Guy; E Tur; S Bjerke; H I Maibach
Journal:  J Am Acad Dermatol       Date:  1985-06       Impact factor: 11.527

4.  Regional variation in percutaneous absorption in man: measurement by the stripping method.

Authors:  A Rougier; D Dupuis; C Lotte; R Roguet; R C Wester; H I Maibach
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

5.  The isolated perfused porcine skin flap (IPPSF). I. A novel in vitro model for percutaneous absorption and cutaneous toxicology studies.

Authors:  J E Riviere; K F Bowman; N A Monteiro-Riviere; L P Dix; M P Carver
Journal:  Fundam Appl Toxicol       Date:  1986-10

Review 6.  Cutaneous pharmacokinetics: 10 steps to percutaneous absorption.

Authors:  R C Wester; H I Maibach
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

7.  Variations in percutaneous absorption of testosterone in the rhesus monkey due to anatomic site of application and frequency of application.

Authors:  R C Wester; P K Noonan; H I Maibach
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

8.  Regional variation in percutaneous penetration of 14C cortisol in man.

Authors:  R J Feldmann; H I Maibach
Journal:  J Invest Dermatol       Date:  1967-02       Impact factor: 8.551

9.  Percutaneous penetration of dipyrithione in man: effect of skin color (race).

Authors:  J H Wedig; H I Maibach
Journal:  J Am Acad Dermatol       Date:  1981-10       Impact factor: 11.527

10.  In vivo and in vitro percutaneous absorption and skin evaporation of isofenphos in man.

Authors:  R C Wester; H I Maibach; J Melendres; L Sedik; J Knaak; R Wang
Journal:  Fundam Appl Toxicol       Date:  1992-11
View more
  7 in total

1.  Validation of a static Franz diffusion cell system for in vitro permeation studies.

Authors:  Shiow-Fern Ng; Jennifer J Rouse; Francis D Sanderson; Victor Meidan; Gillian M Eccleston
Journal:  AAPS PharmSciTech       Date:  2010-09-15       Impact factor: 3.246

2.  Human cadaver skin viability for in vitro percutaneous absorption: storage and detrimental effects of heat-separation and freezing.

Authors:  R C Wester; J Christoffel; T Hartway; N Poblete; H I Maibach; J Forsell
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

3.  Percutaneous drug absorption and administration.

Authors:  I Choonara
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-09       Impact factor: 5.747

4.  Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation.

Authors:  Martin Brunner; Pejman Dehghanyar; Bernd Seigfried; Wolfgang Martin; Georg Menke; Markus Müller
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

Review 5.  Pharmacokinetic characterisation of transdermal delivery systems.

Authors:  B Berner; V A John
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

6.  Comparison of in vitro release rates of acyclovir from cream formulations using vertical diffusion cells.

Authors:  Sumalatha Nallagundla; Srinivas Patnala; Isadore Kanfer
Journal:  AAPS PharmSciTech       Date:  2014-05-14       Impact factor: 3.246

7.  Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidine.

Authors:  K T Kivistö; A Kallio; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.